Shares of Ranbaxy will be in focus on Wednesday, as the company is scheduled to announce its October-December quarter financial performance. Analysts’ views are divided with some expecting the company to post a profit of about ₹130 crore and others believing it could report a loss. However, more than its earnings, the Street will look to the management’s comments on the timeline for resolving regulatory problems, launching Diovan and the anti-viral drug Valcyte, in the US. The stock has gained about two per cent on Tuesday at ₹321.75.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.